{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:48:55Z","timestamp":1770799735904,"version":"3.50.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T00:00:00Z","timestamp":1374105600000},"content-version":"vor","delay-in-days":3151,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1016\/j.bbadis.2004.09.001","type":"journal-article","created":{"date-parts":[[2004,9,18]],"date-time":"2004-09-18T15:07:10Z","timestamp":1095520030000},"page":"70-80","source":"Crossref","is-referenced-by-count":22,"title":["PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice"],"prefix":"10.1016","volume":"1739","author":[{"given":"C.S.M.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.R.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2004.09.001_bib1","first-page":"965","article-title":"Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators, Bailli\u00e9re's","volume":"7","author":"Hershko","year":"1994","journal-title":"Clin. Haematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron chelation therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib3","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S1357-2725(03)00046-3","article-title":"Beta-thalassaemia: emergence of new and improved iron chelators for treatment","volume":"35","author":"Wong","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mlc.2001.114105","article-title":"The controversial role of deferiprone in the treatment of thalassemia","volume":"137","author":"Richardson","year":"2001","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(02)09740-4","article-title":"Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia","volume":"360","author":"Anderson","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2004.09.001_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1006\/bcmd.2002.0510","article-title":"Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial","volume":"28","author":"Maggio","year":"2002","journal-title":"Blood Cells Mol. Diseases"},{"key":"10.1016\/j.bbadis.2004.09.001_bib7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2165\/00002018-200326080-00003","article-title":"Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine","volume":"26","author":"Kontoghiorghes","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.bbadis.2004.09.001_bib9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199808133390701","article-title":"Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major","volume":"339","author":"Olivieri","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/blood.V91.1.295","article-title":"Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients","volume":"91","author":"Hoffbrand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2004.04946.x","article-title":"Purging iron from the heart","volume":"125","author":"Hershko","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00277-003-0820-0","article-title":"Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major","volume":"83","author":"Wu","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib13","first-page":"21","article-title":"Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children","volume":"41","author":"Gomber","year":"2004","journal-title":"Indian Pediatr."},{"key":"10.1016\/j.bbadis.2004.09.001_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","article-title":"Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent","volume":"97","author":"Ponka","year":"1979","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbadis.2004.09.001_bib15","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0304-4165(79)90100-4","article-title":"A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents","volume":"586","author":"Ponka","year":"1979","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.09.001_bib16","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2141.1979.tb03771.x","article-title":"Effective iron chelation following oral administration of an isoniazid pyridoxal hydrazone","volume":"43","author":"Hoy","year":"1979","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.1980.tb07147.x","article-title":"Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone","volume":"45","author":"Cikrt","year":"1980","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.1840150323","article-title":"Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture","volume":"15","author":"Baker","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.bbadis.2004.09.001_bib19","first-page":"112","article-title":"Pyridoxal isonicotinoyl hydrazone: an effective chelator after oral administration","volume":"27","author":"Brittenham","year":"1990","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0022-2143(99)90173-7","article-title":"Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs","volume":"134","author":"Becker","year":"1999","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0925-4439(01)00041-2","article-title":"Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron","volume":"1536","author":"Richardson","year":"2001","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.09.001_bib22","unstructured":"D.R. Richardson, P.V. Bernhardt, E. Becker, Iron Chelators and Uses Thereof, International Patent Application No. PCT\/AU00\/01050. 2000 4th September, 2000."},{"key":"10.1016\/j.bbadis.2004.09.001_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00775-002-0434-3","article-title":"Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease","volume":"8","author":"Chaston","year":"2003","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/1531-8249(199905)45:5<673::AID-ANA20>3.0.CO;2-Q","article-title":"Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia","volume":"45","author":"Delatyki","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/84818","article-title":"Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe\u2013S enzyme deficiency followed by intramitochondrial iron deposits","volume":"27","author":"Puccio","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbadis.2004.09.001_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1357-2725(00)00067-4","article-title":"Frataxin: its role in iron metabolism and the pathogenesis of Friedreich's ataxia","volume":"33","author":"Becker","year":"2001","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1071-9091(03)00025-1","article-title":"Friedreich ataxia","volume":"10","author":"Pandolfo","year":"2003","journal-title":"Semin. Pediatr. Neurol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib28","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood.V99.10.3813","article-title":"Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterisation of frataxin expression compared to molecules involved in iron metabolism and hemoglobinisation","volume":"99","author":"Becker","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib29","doi-asserted-by":"crossref","first-page":"25943","DOI":"10.1074\/jbc.C400107200","article-title":"Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis","volume":"279","author":"Yoon","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1651-2227.2004.tb03061.x","article-title":"Functional studies of frataxin","volume":"93","author":"Isaya","year":"2004","journal-title":"Acta Paediatr., Suppl."},{"key":"10.1016\/j.bbadis.2004.09.001_bib31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/hmg\/8.3.425","article-title":"The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis","volume":"8","author":"Wong","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2004.09.001_bib32","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1023\/B:NERE.0000014826.00881.c3","article-title":"Role of oxidative damage in Friedreich's ataxia","volume":"29","author":"Bradely","year":"2004","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.bbadis.2004.09.001_bib33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s007750100258","article-title":"Unprecedented oxidation of a biologically active aroylhydrazone chelator catalysed by iron(III): serendipitous identification of diacylhydrazone ligands with high iron chelation efficacy","volume":"6","author":"Bernhardt","year":"2001","journal-title":"J. Biol. Inorg. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/ejic.200390146","article-title":"Structural variations and formation constants of first row transition metal complexes of biologically active aroylhydrazones","author":"Armstrong","year":"2003","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib35","first-page":"147","article-title":"Heart cells in culture: a model of myocardial iron overload and chelation","volume":"106","author":"Link","year":"1985","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib36","first-page":"245","article-title":"Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine: studies in rat heart cells in culture","volume":"122","author":"Hershko","year":"1993","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0022-2143(96)90095-5","article-title":"Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron anthracycline interaction","volume":"127","author":"Link","year":"1996","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0047-6374(97)00129-2","article-title":"On the degradability and exocytosis of ceroid\/lipofuscin in cultured rat cardiac myocytes","volume":"100","author":"Terman","year":"1998","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.bbadis.2004.09.001_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1242\/dev.114.1.173","article-title":"The involvement of adherens juction components in myofibrillogenesis in cultured cardiac myocytes","volume":"114","author":"Goncharova","year":"1992","journal-title":"Development"},{"key":"10.1016\/j.bbadis.2004.09.001_bib40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/mol.63.4.849","article-title":"Anthracyclines induce accumulation of ferritin iron in normal and neoplastic cells: inhibition of the ferritin Fe mobilization pathway","volume":"63","author":"Kwok","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-4889(90)90018-9","article-title":"The uptake of iron and transferrin by the human malignant melanoma cell","volume":"1053","author":"Richardson","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.09.001_bib42","doi-asserted-by":"crossref","first-page":"13972","DOI":"10.1016\/S0021-9258(19)49665-8","article-title":"Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate","volume":"267","author":"Richardson","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib43","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V89.8.3025","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents: II. The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone","volume":"89","author":"Richardson","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib44","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.V76.11.2389.2389","article-title":"Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice","volume":"76","author":"Porter","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib45","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood.V87.8.3477.bloodjournal8783477","article-title":"Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: examination of the intermediates involved in iron metabolism","volume":"87","author":"Richardson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib46","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1182\/blood.V86.11.4295.bloodjournal86114295","article-title":"The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents","volume":"86","author":"Richardson","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib47","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1182\/blood.V94.2.781","article-title":"The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: the effect of the ligands on molecular targets involved in proliferation","volume":"94","author":"Darnell","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jcb.240530419","article-title":"Purification of a novel glycosylated ferritin from horse heart","volume":"53","author":"Campbell","year":"1993","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib49","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1042\/bj2450447","article-title":"A new form of ferritin heterogeneity explained. Isolation and identification of a nineteen-amino-acid-residue fragment from siderosomal ferritin of rat liver","volume":"245","author":"Andrews","year":"1987","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2004.09.001_bib50","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V97.4.1115","article-title":"ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture","volume":"97","author":"Hershko","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0091270003253350","article-title":"Safety tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia","volume":"43","author":"Galanello","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib52","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/S0968-0896(01)00207-3","article-title":"3-Hydroxy (4H)-benzopyran-4-ones as potential iron chelating agents in vivo","volume":"9","author":"Ferrali","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbadis.2004.09.001_bib53","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<545::AID-JPS12>3.0.CO;2-J","article-title":"The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue","volume":"89","author":"Yokel","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2004.09.001_bib54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0304-4165(88)90197-3","article-title":"Effect of pyridoxal isonicotinoyl hydrazone (PIH) and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes","volume":"967","author":"Ponka","year":"1988","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.09.001_bib55","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-2143(98)90180-9","article-title":"Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease","volume":"131","author":"Richardson","year":"1998","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib56","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V91.11.4368","article-title":"Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone","volume":"91","author":"Blaha","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib57","first-page":"99","article-title":"Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal","volume":"98","author":"Hershko","year":"1981","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.bbadis.2004.09.001_bib58","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2002-08-2382","article-title":"Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells","volume":"101","author":"Link","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2004.09.001_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-4157(96)00014-7","article-title":"The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells","volume":"1331","author":"Richardson","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2004.09.001_bib60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.10348","article-title":"Iron chelators for the treatment of iron overload disease: the relationship between structure, redox activity and toxicity","volume":"73","author":"Chaston","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbadis.2004.09.001_bib61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0167-4889(92)90131-T","article-title":"A low-spin iron complex in human melanoma and rat hepatoma cells and a high-spin iron(II) complex in rat hepatoma cells","volume":"1135","author":"St. Pierre","year":"1992","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443904001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T20:02:50Z","timestamp":1624651370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443904001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["S0925443904001577"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2004.09.001","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}